Equasens Société anonyme (EQS) H1 2026 earnings summary

Executive summary

• H1 2026 revenue reached €124.5m, up 7.3% year-over-year, driven by acquisitions and integration of new businesses.

• Annual recurring revenue (ARR) rose 8.8% to €111.1m, with a strong organic component.

• Net profit increased by 10.5% to €20.0m, reflecting improved profitability and disciplined cost management.

• Growth was supported by the Erevo, Novaprove, and DIS acquisitions, and initial benefits from France's Ségur digital healthcare program.

Financial highlights

• Current EBITDA grew 11.9% to €33.3m, with margin up to 26.8% from 25.7% in H1 2025.

• Current operating income rose 11.9% to €23.7m, with margin improving to 19.0%.

• Basic EPS increased 9.9% to €1.26.

• Net cash position increased to €93.2m as of June 30, 2026, up €9.6m from December 2025.

• Operating cash flow reached €33.1m, supporting investments and higher equipment inventories.

Outlook and guidance

• Focus remains on strengthening leadership in digital healthcare solutions across Europe.

• Continued investment in AI integration, SaaS/cloud solutions, and leveraging Wave 2 of the Ségur Reform.

• Strategy emphasizes recurring revenue, high customer retention, and targeted investments in high-potential segments.